April 27, 2004
Source: Eclipse Diagnostics, Inc.
At the 56th Annual American Academy of Neurology Meeting in San Francisco, California, Large Scale Biology Corporation (NASDAQ: LSBC) announced today further progress through its wholly-owned subsidiary, Eclipse Diagnostics, Inc., in the development of its proprietary BAMF™ Technology for the early diagnosis of life-threatening disease.
In an ongoing collaboration, researchers at Wake Forest University Baptist Medical Center and Eclipse Diagnostics, Inc., using the BAMF™ Technology, have reported the presence of distinct proteomic signatures in blood serum from multiple sclerosis patients. The results, entitled, "A Blood Test to Diagnose Multiple Sclerosis: Use of MALDI/TOF and Serum Proteomic Pattern Analysis," were presented today at the meeting and is co-authored by Jagannadha R. Avasarala, M.D., Ph.D. of Wake Forest University and Gary M. Wolfe, Ph.D., Senior Vice President and Chief Scientific Officer, Eclipse Diagnostics, Inc.
Kevin J. Ryan, President and CEO of LSBC, stated, "These findings are further confirmation in our belief that Eclipse Diagnostics, Inc. proprietary BAMF™ Technology will lead to early diagnosis of diseases such as multiple sclerosis and various cancers and thus lead to improved patient outcomes through earlier medical intervention."
Further information about BAMF™ Technology can be found on the company's website (www.eclipsediagnostics.com).
About Large Scale Biology Corporation
Large Scale Biology uses its biomanufacturing, functional genomics and proteomics technologies to develop and manufacture drugs, vaccines and diagnostics for effective treatment of disease. Corporate offices, Eclipse Diagnostics, Inc., the Genomics Division, the Proteomics Division, and Biopharmaceutical Development laboratories are headquartered in Vacaville, California, and the Company's commercial-scale biomanufacturing facility is located in Owensboro, Kentucky. For more information about Large Scale Biology Corporation, visit the Company's website at www.lsbc.com.
This release contains forward-looking statements about applications of LSBC's technologies and potential markets. These forward-looking statements involve risks, uncertainties and situations that may cause our actual results to differ materially from those implied by these statements, including our ability to commercialize applications of our technologies, the ability of our collaborators to generate demand for the diagnostic applications we provide them, the effectiveness of our and our collaborators' technologies to produce specific diagnostics or provide services and/or in a cost-effective manner, any difficulties or delays in obtaining regulatory approval to test and market such diagnostics or services, and the requirement of substantial funding for us to preserve our technology base and diagnostic applications. We cannot guarantee future results. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this release. For a further list and description of such risks and uncertainties see the reports filed by Large Scale Biology Corporation with the Securities and Exchange Commission, including our reports on Forms 10-K and 10-Q. Except as required by law, we do not undertake to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
LSBC® and BAMF™ are trademarks of Large Scale Biology Corporation.
Copyright © 2004, Market Wire